Mitochondrial Medicine Program Clinical Studies

1 - 4 of 4

Mitochondrial Myopathy Rating Scale

The purpose of this research study is to 1) validate the use of surveys such as fatigue scales, Mitochondrial Disease scales, and quality of life scales, 2) validate clinical exams, such as muscle strength tests, and the 6 minute walk test, and 3) to define the natural history of the disease in the Mitochondrial Disease patient population.

Elamipretide for Adult Patients with Primary Mitochondrial Disease

The goal of this study is to evaluate the safety and efficacy of an investigational drug called "Elamipretide" in adult patients with mitochondrial disease. "Investigational" means the study drug has not been approved by the U.S. Food and Drug Administration (FDA) and its use in this study is experimental.

The study will last for approximately 13 months and will include at least 7 outpatient visits at CHOP, where participants will be provided the study drug (randomized to active drug or placebo) and monitored for safety.  The clinical trial also involves blood and urine tests, cardiac tests, physical exercise tests, and other study procedures.  For more information:

You will also receive travel support and reimbursement for related expenses.

Astellas Clinical Trial for ASP0367

We are recruiting patients with genetically confirmed primary mitochondrial myopathy who are at least 18 years old for a randomized, double-blind, placebo-controlled study of a new drug to treat this disorder. This study is designed to assess whether experimental drug ASP0367 is safe and effective for patients with mitochondrial myopathy. Participants will take the study drug orally once per day. This is a placebo-controlled study followed by an open-label extension, which means that during the treatment period some patients will receive ASP0367 and some will receive a placebo, which does not contain active study medication. At the end of the treatment period all participants will be offered ASP0367 for a 6-month period.

The study will last roughly 1 year and 8 months and involves at least 11 visits to CHOP, remote interviews, video assessments, and home visits for additional blood draws. If you are interested in learning more about this study, please visit or contact the study team for additional information.

CrCEST MRI in Mitochondrial Disease

The Mitochondrial Medicine Program at the Children’s Hospital of Philadelphia is conducting a study focusing on non-invasive MRI procedures to measure biological activity within leg muscles of individuals, including both healthy volunteers and those with mitochondrial disease. This type of MRI is for research only, and it is not currently approved by the FDA. There is no direct benefit, but this research may contribute to future mitochondrial medicine. Your participation will last for approximately half a day during a visit at CHOP. We hope this research will contribute to the current knowledge of mitochondrial disease and improve diagnostic approaches. To learn more or inquire about this research study, please contact Sara Nguyen (